Introduction
Vascular growth factors have been the focus of considerable attention with regard to their potential role in the pathogenesis of vascular injury and disease. Numerous growth factors have been cited as being pivotal, important or at least relevant to the development of large vessel atherosclerosis. I In addition, specific growth factors have been implicated in the pathogenesis of neointimal hyperplasia and vascular stenosis following the traumatic endothelial denudation that results from angioplasty. 2 With regard to microvascular disease, vascular growth factors coordinate the biological events of angiogenesis and are thus relevant to the angiogenesis that supports tumour growth and the neovascularization that complicates diabetes mellitus. Because of the relevance of growth factors to vascular disease pathophysiology, the biology of existing and emerging vascular growth factors has become an area of intense interest, not least of all because they provide a target for future therapeutic manipulation.
This review focuses on a recently described family of vascular growth factors, the vascular permeability/vascular endothelial growth factors (VPFNEGF). 3, 4 As the name implies, this closely related family of growth factors act exclusively on vascular endothelial cells to potently initiate two key biological events: (1) marked increases in vascular endothelial permeability.v" and (2) endothelial cell proliferation, leading to angiogenesis,":" These properties suggest that VPFNEGF could play an important role in the development of endothelial dysfunction and pathological neovascularization in various disease states. Nevertheless, these properties also suggest that, although increased VPFNEGF production may be detrimental in some disease processes, the controlled, local administration of VPFNEGF may be of therapeutic benefit in other clinical situations, for instance, in promoting angiogenesis in criti-calIy ischaemic tissues. This review details our current knowledge of the biology of VPFNEGFs and their receptors and describes how the biological properties of this fam- 
Characterization and structure of the VPFNEGF family
A VPF was originally identified in the supernatant from cultured tumour cells as a factor that could dramatically increase the permeability of guinea pig subcutaneous vessels in the Miles assay.4-6.10.11 Simultaneously, a potent endothelial cell-specific mitogen, named 'vascular endothelial growth factor' (VEGF) was isolated from the conditioned media of folliculostellate cells. It was soon recognized that VPF and VEGF described the properties of a single family of glycopeptides. To date, molecular cloning of the cDNAs for VPFNEGF has revealed the existence of five closely related members of the VPFNEGF family, each formed by alternative mRNA splicing from a single eight exon gene.!"!" The five VPFNEGF mRNAs encode proteins of 121, 145, 165, 189and 206 amino acids respectively. The VPFNEGF gene has high homology with placenta-derived growth factor. It also has limited homology with platelet-derived growth factor (PDGF) (only 18% homology with PDGF-B) but does contain the eight conserved cysteine residues that are the hallmark of the PDGF family. [15] [16] [17] [18] [19] [20] Microsequencing of the VPFNEGF has revealed that the NH 2-amino acid sequence of all five peptides is preceded by a typical 26 amino acid hydrophobic signal sequence, typical of that observed in secreted peptides.I'r" The mature VPFNEGF peptide is generated after cleavage of the signal sequence. Although the genes for all peptides encode for a signal sequence, not all of the peptides are secreted by their generator celI. VPFNEGFI2\ and VPFNEGF I65 are secreted, whereas VPFNEGF I65 and VPFNEGF 206 are not efficiently secreted. To date, the characterization and fate of VPFNEGF I45 are unclear. Analysis of a variety of tissues and cultured cells demonstrates that the transcript encoding VPFNEGF I65 is the most abundant product of the VPFNEGF gene, except in the placenta where VPF/VEGF I21 is most abundant."
The structure of the VPFNEGF proteins has been best characterized for VPFNEGF I65. This is a basic heat-and specific mitogen. It can stimulate the proliferation of cultured vascular endothelial cells from a variety of sources at picomolar concentrations. 7,'2,J3,J8,32 Unlike many other growth factors. the mitogenic action of VPFNEGF is restricted to the vascular endothelium. It is also noteworthy that VPFNEGF is secreted as an active peptide. which contrasts with many of the better-characterized vascular growth factors. such as acidic and basic fibroblast growth factors and PDGFs. which lack a signal peptide for secretion by the generator cell and thus usually become available to the target cell only after generator cell death.
Substantial evidence is now accumulating to suggest that VPFNEGF plays a significant role in vivo in the regulation of angiogenesis. VPFNEGF induces a striking angiogenic response when applied to chick chorioallantoic membranes-" and rat and rabbit corneas.v'-" This demonstrates that VPFNEGF has the ability to trigger independently the entire sequence of biological events that culminate in new blood vessel growth.l"" VPFNEGF mRNA is abundantly expressed in a variety of highly vascularized tissues and VPFNEGF receptors are also localized to sites of neoangiogenesis. 7, 8, 39, 40 Some of the best evidence for a strong spatial and temporal relationship between VPFNEGF expression and angiogenesis has come from the study of tumours.v'r" Tumour deposits are frequently surrounded by angiogenesis. which supports the growth and invasion of tumours within tissues. Several studies have demonstrated the abundant expression of VPFNEGF mRNA and peptide adjacent to these new vessels.i'r" Moreover many types of tumour are capable of producing VPFNEGF. which stimulates local angiogenesist'r": An important corroboration of the relevance of VPFNEGF to tumour angiogenesis comes from the observation that anti-VPFNEGF neutralizing antibodies can inhibit both tumour angiogenesis and tumour growth in animals."
In addition to its permeabilizing and angiogenic properties. VPFNEGF has been reported to have other actions on endothelial function (Table I) . It has been reported that VPFNEGF can induce the expression and synthesis of tissue factor and promote the release of Von Willebrand factor by endothelial cells." VPFNEGF has also been reported to induce interstitial collagenase mRNA expression and protein production by endothelial cells but not fibroblasts." It also induces urokinase-type plasminogen activator (u-PA) mRNA and protein and also plasminogen activator
B Williams
acid-stable. dimeric glycoprotein formed by the linkage of two identical monomers. linked by disulphide bridges. with a molecular weight of approximately 45 kDa. 23.24 VPFNEGF I65 is completely inactivated by reducing agents such as dithiothreitol and l3-mercaptoethanol. and the monomers are biologically inactive and do not bind to VPFNEGF receptors on vascular endothelial cells." The VPFNEGF proteins contain a single glycosylation site and recombinant human VPFNEGF l65 monomers can exist in glycosylated (23 kDa) and deglycosylated (18 kDa) forms.18.19.26 Deglycosylation does not affect the secretion of VPFNEGF I65• nor does it influence its binding to vascular endothelial cells. its vascular permeabilizing action or its mitogenic activity." It is unknown whether glycosylation is essential or permissive for the other recognized functions of VPFNEGF l65 in endothelial cells (see below).
There are clear differences in the heparin-binding properties of the various VPFNEGF species. VPFNEGF I2I binds weakly to heparin whereas the 165 and 189 species are more readily bound to it. The functional significance of these differences in heparin binding are unclear but they may. play a role in restricting and targeting some VPFNEGF species to a local site of action following secretion. For example. the binding of VPFNEGF165 to its receptors on vascular endothelial cells is greatly enhanced in the presence of heparin and can be reduced by depleting heparin from the endothelial cell surface with heparinases." Further work is needed to clarify the relevance of heparin binding to VPFNEGF function and localization.
The various species of VPFNEGF appear to have subtle differences in their profile of biological activity. There are also differences in the relative potencies of the VPFNEGF species with regard to their vascular permeabilizing actions and mitogenic activity. All forms of VPFNEGF are potent vascular permeabilizing agents but the two longer cell-associated forms (189 and 206) appear to be less effective endothelial mitogens."
Functions of VPFNEGF
VPFNEGF represents a family of closely related multifunctional peptides with a powerful potential to influence vascular growth and function. The intradermal injection of VPFNEGF causes a rapid. dramatic but transient increase in microvascular permeability without promoting endothelial cell damage.v" These effects occur at concentrations well below 1 nmol/l, indicating that VPFNEGF is an extremely potent vascular permeabilizing agent. To date. VPFNEGF is the most potent vascular permeabilizer ever identified in human biology; on a molar basis. it is 50000 times more potent than histamine.' It is unknown whether a specific VPFNEGF receptor subtype (see below) is responsible for the vascular permeabilizing actions of VPFNEGF. Moreover. the mechanism whereby endothelial permeability is increased is poorly defined. although the possibilities include increased interendothelial gap formation and an increase in the transendothelial transport of macromolecules across an intracellular network of vesicular-vacuolar organelles.l":" Whatever the mechanism. it is powerful and results from endothelial dysfunction rather than endothelial injury and/or denudation.
VPFNEGF is also a powerful, vascular endothelial cell-Vascular Medicine 1996; 1: 251-258 inhibitor-I (PAl-I) in microvascular endothelial cells. 4 8 The induction of these enzymes has considerable relevance to angiogenesis because they will induce local extracellular matrix proteolysis and basement membrane degradation, both of which are key events in the angiogenic cascade."
VPFNEGF also stimulates hexose transport by vascular endothelial cells," as well as promoting the migration of monocytes to the endothelium and their activation."
Finally, VPFNEGF applied directly to isolated segments of canine coronary arteries has been shown to induce endothelium-dependent relaxation." It is unknown whether this response involves the release of nitric oxide or alternative mechanisms. Together, these actions reveal that VPFNEGF peptides represent a multifunctional cytokine family with a wide spectrum of activities that could playa key role in normal vascular function and growth. Furthermore, it is conceivable that excess production of VPFNEGF could play an influential role in the pathogenesis of endothelial dysfunction and neovascularization in a variety of disease states.
VPFNEGF receptors
VPFNEGF exerts its potent actions on vascular function by binding to highly specific receptors. Although these receptors are predominantly located on vascular endothelial cells, VPFNEGF binding to lens epithelial cells, corneal endothelial cells and human melanoma cells has also been demonstrated. Interestingly, however, VPFNEGF is mitogenic only for endothelial cells; thus the function of VPFNEGF receptors in these other tissues is unclear. Two types of high-affinity VPFNEGF receptors have so far been identified: the fit receptor and the KDRlfik receptor. [52] [53] [54] [55] [56] The fit gene encodes a tyrosine kinase receptor of the PDGF receptor subfamily." The fit receptor has an extracellular domain comprising seven immunoglobulinlike loops (unlike the PDGF receptor, which has five), a single transmembrane-spanning domain and a split tyrosine kinase domain.52 This receptor structure implies that the fit receptor is likely to signal intracellularly via tyrosine phosphorylation. Surprisingly, it has not yet been demonstrated that VPFNEGF binding to the fit receptor induces tyrosine autophosphorylation. However, in one study the binding of VPFNEGF to oocytes transfected with fit mRNA resulted in a fivefold increase in Ca 2 + efflux, illustrating that VPFNEGF can induce a biological response via the fit receptor."
The second high-affinity tyrosine kinase receptor for VPFNEGF is encoded by the KDRlfik-1 gene.53.55-58 This receptor is structurally similar to the fit receptor and has been shown to undergo autophosphorylation on tyrosine Upon binding VPFNEGFI65.58 Thus, VPFNEGF I65 binds to two structurally similar but distinct and highly specific receptors on vascular endothelial cells. Our understanding of the intracellular signal transduction pathways that are activated via these receptors is still rudimentary. Moreover, it is unclear whether each receptor is capable of transducing the full repertoire of biological responses to VPFNEGF or whether each receptor subtype signals a specific response (i.e. either permeability or angiogenesis).
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Vascular permeability/vascular endothelial growth factors 253 VPFNEGF production by human vascular tissue VPFNEGF mRNA has been detected in a variety of tissues including: normal lung, kidney, heart and adrenal gland. pituitary gland, brain, liver, spleen, gastric mucosa, breast and reproductive tissues.t" The fact that the main site of action of VPFNEGF is the vascular endothelium implies that a logical site for its production would be the underlying vascular smooth muscle cell (VSM cell). We have demonstrated that cultured human VSM cells (arterial and venous) express abundant quantities of a single VPFNEGF mRNA transcript (4.2 kb) and synthesize and secrete the peptide VPFNEGFI65.59-6' Cultured human endothelial cells do not express VPF mRNA. 59 Using in situ hybridization, we have recently examined VPFNEGF mRNA expression by healthy human arteries and have shown that VPFNEGF mRNA is not expressed by the vascular endothelium or adventitial cells; however, it is expressed by the vascular smooth muscle cells of the media (unpublished observations). VPFNEGF mRNA expression by healthy human arteries is consistently observed but the level of mRNA expression is much less than that observed at other sites of known abundant VPFNEGF mRNA expression such as human kidney glomeruli and in the region of tumour angiogenesis. These observations suggest that, in healthy blood vessels, there is low constitutive expression of VPFNEGF mRNA within medium-to large-sized human arteries and that this expression is restricted to the VSM cell. We have proposed that human VSM cells produce VPFNEGF and that the peptide is released to act as a paracrine hormone to influence the growth, permeability and other functions of the overlying vascular endothelium.l"?' We have also consistently detected VPFNEGF I65 in the serum of healthy adult humans (unpublished observations). The source of this circulating VPFNEGF in humans is unclear but does imply that, as well as acting as a local paracrine factor wIthin blood vessels, VPFNEGF may also act to influence vascular endothelial function at sites distant from its site of production.
Stimuli for VPFNEGF production by vascular tissues
Various stimuli have now been shown to increase VPFNEGF expression, synthesis and release by cultured VSM cells ( Figure I) . First, we have demonstrated that serum, PDGF, arginine vasopressin (via the V, receptor) and angiotensin II (via the AT, receptor) rapidly induce VPFNEGF mRNA expression (within 3 hours) in human VSM cells, and that this is associated with a measurable increase in VPFNEGF I65 peptide secreted into the culture media overlying the cells by 12 hours. 59-61 Others have shown that transforming growth factor 131 (TGFI3,) also increases VPFNEGF mRNA expression by human VSM cells, with the effect peaking between 3 and 6 hours."?
Secondly, hypoxia is also a potent stimulus for angiogenesis in vivo and is also powerful stimulus for VPFNEGF mRNA expression in a variety of cell types including VSM cells. 62-{>5 Finally, cytokines such as basic fibroblast growth factor (bFGF) have been shown to induce VPFNEGF mRNA expression by cultured rabbit VSM cells.":' and bFGF and hypoxia have also been shown to act synergistically in inducing such expression by VSM cells.v' revealing Various factors influence the production of VPFNEGF by vascular smooth muscle cells. We propose that VPFNEGF peptide acts either as a paracrine factor to modulate the function of the overlying vascular endothelium, or as a systemic factor, exerting its actions on endothelium distal from its site of production, or both the potential for various stimuli for VPFNEGF production by VSM cells to interact in vivo. It is also noteworthy that VPFNEGF may also act synergistically with cytokines such as bFGF to induce angiogenesis. These observations reveal the complexity of the mechanisms regulating angiogenesis and suggest that. in addition to direct angiogenic factors such as bFGF and VPFNEGF. numerous other cytokines and hypoxia could act as 'indirect' angiogenic factors via the induction of VPFNEGF expression and synthesis within VSM cells.
Potential role for VPF in vascular disease
Review of the various activities of VPFNEGF suggests that the local production of this peptide by VSM cells would have a profound effect on the function of the overlying vascular endothelium. Our in situ hybridization studies suggest that in normal healthy. medium-to large-sized arteries the basal expression of VPFNEGF mRNA is very low. Perhaps this low constitutive expression of VPFNEGF by VSM cells plays a role in regulating the normal growth and repair processes of the vascular endothelium and also influences its basal permeability.
If the aforementioned data obtained in VSM cell culture Vascular Medicine 1996; 1: 251-258 are relevant to the situation in vivo. then the generation of numerous cytokines and/or the development of hypoxia within blood vessels or surrounding tissues would have the potential to upregulate markedly both VPFNEGF expression and synthesis within the media of the blood vessel wall. Such a response. if sustained, could lead to endothelial dysfunction. It is generally accepted that endothelial dysfunction is a prominent early event in the pathogenesis of atherosclerosis. I This usually manifests as an increase in vascular permeability to circulating macromolecules. Monocyte migration and adhesion to the endothelium also occur early in the sequence of events leading to the formation of the early atherosclerotic lesion. I Endothelial dysfunction is also prominent in diabetes mellitus where it is associated with the premature development of macrovascular and microvascular disease. 6 6--6 8 The latter is characterized by widespread neovascularization, increased vascular permeability and markers of endothelial dysfunction such as Von Willebrand factor release. 6 6-68 All of these events could potentially result from the local action of increased levels of VPFNEGF peptides or increased expression of VPFNEGF receptors on the vascular endothelium. The attractive feature of this hypothesis is that many of the factors that can induce VPFNEGF synthesis (i.e. hypoxia, POGF, bFGF and angiotensin II) have already been implicated in the pathogenesis of vascular disease and angiogen-esis.1. [62] [63] [64] [65] It is thus conceivable that VPFNEGF is an important final common pathway in the generation of various aspects of endothelial dysfunction and pathological angiogenesis in various disease states. Moreover, if VPFNEGF is a key player in the final common path of endothelial dysfunction and neovascularization, then the specific targeting of the VPFNEGF receptors may provide a useful therapeutic approach to limiting endothelial dysfunction and neovascularization in various diseases and diabetes microangiopathy in particular. With regard to the latter, when compared with diabetic individuals without evidence of proliferative retinopathy, VPFNEGF levels have been shown to be elevated in the eyes of those diabetic patients who do show evidence of ocular neovascularization.s?
Potential therapeutic role for VPFNEGF
Angiogenesis is not always an undesirable event. On the contrary, local angiogenesis in ischaemic tissues (e.g. myocardial or lower limb ischaemia) plays an important role in preserving and enhancing tissue viability. Moreover, there are specific clinical circumstances when it may be desirable to enhance re-endothelialization (e.g. following angioplasty). Angioplasty inevitably results in endothelial denudation, which has been implicated in the development of intimal hyperplasia and subsequent vascular stenosis.":" In such circumstances, the local delivery of direct angiogenic factors such as VPFNEGF to stimulate endothelial regeneration could potentially lead to a rapid restoration of vascular integrity. In this regard, Asahara et al 72 recently examined the effects of local delivery of VPFNEGF to carotid angioplasty sites in a rat experimental model. In this study, following balloon angioplasty to the carotid artery, rats received either a 30 min infusion of VPFNEGF I65 locally targeted to the angioplasty site, or a placebo infusion. Re-endothelializtion of the angioplasty site was assessed after 4 weeks and was clearly superior in arteries previously exposed to VPFNEGF compared with arteries treated with placebo. Moreover neointimal thickening, the prelude to vascular restenosis, was significantly attenuated in the VPFNEGF-treated vessels." This latter finding is Particularly intriguing because it supports the notion that endothelial integrity is essential to suppress neointimal hyperplasia postangioplasty. Furthermore, the use of VPFNEGF is potentially superior to other endothelial growth factors in this regard because the mitogenic action of VPFNEGF is highly restricted to the endothelium. This Contrasts with the actions of other endothelial mitogens such as bFGF, which also acts as a smooth muscle cell mitogen. As smooth muscle cell proliferation is likely to play an important role in neointimal thickening and matrix deposition, this dual mitogenic action of bFGF suggests that it may be less desirable than VPFNEGF as a 'local' therapeutic agent postangioplasty. These preliminary experimental observations raise the intriguing possibility that re-endothelialization postangioplasty could be enhanced by the local delivery of VPFNEGF via topical gene transfer at the time of angioplasty.
As exciting as these early results may seem. they should be balanced by a word of caution. VPFNEGF is not only an endothelial mitogen; it also increases endothelial per-Vascular Medicine 1996; 1: 251-258
Vascular permeability/vascular endothelial growth [actors 255 meability and the development of a procoagulant state on the endothelial surface (see Table I ). Thus, although the endothelium may appear to be structurally normal following VPFNEGF-induced re-endothelialization, it is conceivable that the function of the 'neoendothelium' is abnormal. Longer-term studies are needed to confirm that the apparent short-term benefits of VPFNEGF-mediated re-endothelialization are not offset in the longer term by a local increase in the thrombotic tendency of the VPFNEGFtreated vessel segment and increased local extravasation of fibrinogen and thrombin, both of which could enhance local matrix deposition, vascular smooth muscle cell migration and proliferation and the late development of vascular stenosis.
Another potential clinical application of VPFNEGF is the promotion of angiogenesis and the development of a collateral blood supply in ischaemic tissues. In a rabbit model of hind-limb ischaemia. site-specific transfection of a gene encoding VPFNEGF I65 into the iliac artery was achieved by coating an angioplasty balloon with a hydrogel polymer containing phVPFNEGF I65 .7J Successful transfection and expression were subsequently confirmed and resulted in the significant augmentation of collateral blood flow to the ischaemic hind-limb of these animals and increased capillary density. Furthermore, significant improvements in the haemodynamic deficit of the ischaemic limbs were also documented after VPFNEGF transfection." These results thus established that site-specific arterial transfer of VPFNEGF can successfully be used to induce physiologically significant angiogenesis and improvements in tissue perfusion in animals.
Encouraged by these results. a human study was recently commenced with the objective of determining the safety and potential efficacy of phVEGF I65 arterial gene therapy for therapeutic angiogenesis." Briefly, the recipients of this novel therapy will be men and women~40 years old with critical lower limb ischaemia who are deemed to be unsuitable for surgical or nonsurgical revascularization. A plasmid into which VPFNEGF I65 has been inserted will be applied to the hydrogel polymer coating of a standard angioplasty balloon in a manner similar to that used for the preliminary animal studies cited above. The gene transfer will be performed percutaneously and the response to therapy will be judged on clinical criteria (abolition of rest pain and healing of ischaemic ulcers) as well as angiographic and haemodynamic studies to assess the development of collaterals following gene transfer. The results of this study are eagerly awaited and may herald the beginning of an exciting new era in the management of critical limb ischaemia. They also raise the possibility of similar approaches using VPFNEGF in the management of chronic myocardial ischaemia.
Conclusions
This review has highlighted the emergence of VPFNEGF as a potentially important player in the regulation of endothelial function and angiogenesis in health and disease. The properties of the VPFNEGF family and the prevailing evidence strongly support the notion that VPFNEGF plays a key role in physiological angiogenesis in health and tumour angiogenesis and proliferative microangiopathy in disease.
These observations have already identified important clinical areas where local anti-VPFNEGF therapies might be useful in disease management. for instance in inhibition of tumour growth, or of diabetic microangiopathy.
It is currently less clear whether the powerful vascular permeabilizing properties of VPFNEGF play any role in the pathophysiology of the increased vascular permeability that characterizes many vascular and inflammatory diseases and the proteinuria of many glomerular diseases. If VPFNEGF is playing a substantial role in regulating endothelial permeability in these circumstances then the inhibition of VPFNEGF production or specific inhibition of VPFNEGF receptors within blood vessels or the kidney might provide novel therapies designed to limit this manifestation of disease at these sites.
These and other important questions will best be answered by increasing our understanding of the differential expression and function of the various VPFNEGF isoforms and the development of specific antagonists to identify and then inhibit the functions mediated via the different VPFNEGF receptor subtypes.
The benefits or otherwise of using VPFNEGF in targeted therapeutic angiogenesis are likely to be established sooner. Nevertheless, the two potential benefits -(1) promoting rapid re-endothelialization postangioplasty and (2) inducing new vessel formation in criticalIy ischaemic tissues -must be countered with a caution that reflects our increasing knowledge of the other actions of VPFNEGF. most notably the capacity of VPFNEGF to change the functional characteristics of the endothelium it generates. Defining the relative merits of VPFNEGF as friend or foe in normal vascular physiology. vascular disease and the therapy of ischaemia is a major challenge but one which may yield exciting and novel therapeutic strategies relevant to a wide spectrum of disease.
